Obesity is a significant problem in the US, and an increase in body mass index (BMI) has an unclear effect on outcomes for patients with cervical carcinoma who receive definitive chemoradiation.
Michael C. Roach, MD, Julie K. Schwarz, MD, PhD, Perry W. Grigsby, MD, MBA; Washington University
Purpose and Background: Obesity is a significant problem in the US, and an increase in body mass index (BMI) has an unclear effect on outcomes for patients with cervical carcinoma who receive definitive chemoradiation.
Methods: This retrospective cohort included 490 patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB1 or greater cervical carcinoma who received definitive treatment with chemoradiation therapy consisting of both external beam radiotherapy (EBRT) and brachytherapy between January 1998 and June 2012 at a single institution. The mean follow-up was 50 months. BMI was calculated using the National Institutes of Health online calculator. Primary outcomes were rates of overall survival (OS) and grade 3 or greater complications.
Results: Underweight patients (BMI < 18.5 kg/m2) had an inferior OS when compared with normal-weight (18.5–24.9 kg/m2) and overweight (> 24.9 kg/m2) patients (P = .04) on log-rank analysis. The 5-year OS rate was 58% (15/26) for underweight, 69% (99/143) for normal-weight, and 71% (228/321) for obese patients. Overweight patients had the lowest risk of toxicity (P = .05) on log-rank analysis. The rates of grade 3 or greater bowel or bladder toxicity were 23% for underweight (6/26), 18% for normal-weight (26/143), and 12% for overweight patients (38/321).
Conclusions: Underweight patients have inferior OS and greater complication rates when compared with normal-weight and overweight patients.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.